Improving the inefficient influenza supply path and overcoming additional obstacles to the widespread introduction of new solutions is the aim of ‘Flu diagnosis – Transforming influenza management in Europe’. Using a laboratory-based testing methodology, the aim is to create an easy-to-use and compact solution that will enable bedside medical care for patients at risk of influenza. RealWorld4Clinic aims to improve the limited use of available ‘real world’ data in both drug development and disease management. The lack of real data limits the predictive power of clinical trials and thus the quality of necessary early decision making in drug development – leading to high failure rates and even withdrawal of drugs from the market. Drug-induced cardiac and neuronal toxicities are major complications in clinical practice and are the main cause of problems during early drug development and after market launch. The R2U-Tox-Assay project aims to push the boundaries of medical care with an innovative approach that will strengthen the healthcare system as a whole.
Some innovations also affect our EIT Health Germany Key Account Management: With 36 partners, EIT Health Germany is not only one of the largest co-location centers within EIT Health, but has also been serving the entire DACH region since the beginning of this year Germany, Austria and Switzerland. For the best possible support and advice to our partners, we have restructured our key account management for this year. ‘Your’ Account Manager can be found in the following graphic:
If you have any questions or require further information, please contact ‘your’ key account manager. We look forward to working with you in 2020!